Drug Profile
Pembrolizumab companion diagnostic - Dako/Merck
Alternative Names: Lambrolizumab companion diagnostic - Dako/Merck; PD-L1 IHC 22C3 pharmDxLatest Information Update: 16 Jun 2022
Price :
$50
*
At a glance
- Originator Dako A/S; Merck & Co
- Developer Agilent Technologies; Dako A/S; Merck & Co
- Class Diagnostic agents; Monoclonal antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Triple negative breast cancer; Urogenital cancer